Applied Molecular Transport Inc. is a biopharmaceutical company focused on designing and developing oral and respiratory biologic products for the treatment of diseases like autoimmune, inflammatory, and metabolic disorders. Its leading product candidate, AMT-101, is an oral fusion for the treatment of inflammatory diseases, undergoing Phase II clinical trials. The company's diverse pipeline of product candidates includes AMT-126, an oral fusion of interleukin 22, in Phase I clinical trials.